This is an abbreviated version of Battea’s TherapeuticsMD securities litigation proprietary research. Full case summaries and economic analyses are available to clients through Battea’s litigation monitoring portal. For more information, or to request a demonstration, contact Battea.
Case Filed: April 17, 2017
Securities class action on behalf of all investors who purchased or otherwise acquired TherapeuticsMD common stock between July 7, 2016 and April 9, 2017, pursuant to sections 10(b) & 20(a) of the Securities Exchange Act of 1934.
|Lead Plaintiff Deadline||6/16/2017
The complaint alleges that defendants made false and/or misleading statements and/or failed to disclose that: (1) the company's NDA submission for TX 004HR was deficient; (ii) the company's NDA submission for TX 004HR was not supported by the complete TX 0004HR clinical program and/or the clinical program was deficient; (iii) the company's deficient NDA would likely cause a delay of the FDA's potential approval of the TX 004HR NDA; and (iv) as a result, defendants' statements about TherapeuticsMD's business, operations and prospects were false and misleading.
Brief Company Profile
TherapeuticsMD, Inc. operates as a women's health care product company. The company manufactures and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
|Class Period||7/7/16 - 4/9/17
|Defendant(s)||THERAPEUTICSMD, INC., ROBERT G. FINIZIO AND BRIAN BERNICK
TherapeuticsMD Securities Litigation Price Chart